MA35904B1 - Formulations stabilisées contenant des anticorps anti-ang2 - Google Patents
Formulations stabilisées contenant des anticorps anti-ang2Info
- Publication number
- MA35904B1 MA35904B1 MA37279A MA37279A MA35904B1 MA 35904 B1 MA35904 B1 MA 35904B1 MA 37279 A MA37279 A MA 37279A MA 37279 A MA37279 A MA 37279A MA 35904 B1 MA35904 B1 MA 35904B1
- Authority
- MA
- Morocco
- Prior art keywords
- ang
- antibody
- formulations containing
- containing anti
- stabilized formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Mechanical Engineering (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne des formulations pharmaceutiques comprenant un anticorps qui se lie spécifiquement à l'angiopoïétine 2 (ang -2). Les formulations peuvent contenir outre un anticorps anti-ang -2, un acide aminé au moins, un sucre au moins ou un agent tensioactif non ionique au moins. Les formulations pharmaceutiques de la présente invention présentent un degré sensible de la stabilité des anticorps après un stockage pendant plusieurs mois et après avoir été soumis à des contraintes thermiques et physiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261589427P | 2012-01-23 | 2012-01-23 | |
PCT/US2013/022473 WO2013112438A1 (fr) | 2012-01-23 | 2013-01-22 | Formulations stabilisées contenant des anticorps anti-ang2 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35904B1 true MA35904B1 (fr) | 2014-12-01 |
Family
ID=47633582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37279A MA35904B1 (fr) | 2012-01-23 | 2014-08-07 | Formulations stabilisées contenant des anticorps anti-ang2 |
Country Status (23)
Country | Link |
---|---|
US (1) | US9402898B2 (fr) |
EP (1) | EP2807190B1 (fr) |
JP (1) | JP6113756B2 (fr) |
KR (1) | KR102063028B1 (fr) |
CN (1) | CN104169299B (fr) |
AR (1) | AR089787A1 (fr) |
AU (1) | AU2013212587B2 (fr) |
BR (1) | BR112014017882A2 (fr) |
CA (1) | CA2861062A1 (fr) |
CL (1) | CL2014001930A1 (fr) |
EA (1) | EA033387B1 (fr) |
HK (1) | HK1204631A1 (fr) |
IL (1) | IL233482B (fr) |
JO (1) | JO3533B1 (fr) |
MA (1) | MA35904B1 (fr) |
MX (1) | MX357393B (fr) |
MY (1) | MY164611A (fr) |
NZ (1) | NZ627859A (fr) |
PH (1) | PH12014501628A1 (fr) |
SG (1) | SG11201403792TA (fr) |
TW (1) | TWI615149B (fr) |
UY (1) | UY34587A (fr) |
WO (1) | WO2013112438A1 (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104169299B (zh) | 2012-01-23 | 2018-06-05 | 瑞泽恩制药公司 | 含抗Ang-2 抗体的稳定化制剂 |
US20140227250A1 (en) * | 2012-08-23 | 2014-08-14 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
JP6469644B2 (ja) | 2013-03-15 | 2019-02-13 | アムジエン・インコーポレーテツド | 抗ccr7抗原結合タンパク質に関係する方法および組成物 |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
KR102349370B1 (ko) | 2014-05-26 | 2022-01-10 | 삼성전자주식회사 | 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도 |
KR20170012286A (ko) * | 2014-05-30 | 2017-02-02 | 뉴 잉글랜드 바이오랩스, 인크 | 탈당화 시약 및 방법 |
AU2015328411C1 (en) | 2014-10-06 | 2022-03-03 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
AU2015331602A1 (en) * | 2014-10-17 | 2017-04-27 | Amgen Inc. | Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies |
HUP1400510A1 (hu) * | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
PT3386541T (pt) | 2015-12-07 | 2020-10-12 | Merck Patent Gmbh | Formulação farmacêutica aquosa compreendendo o anticorpo anti-pd-1 avelumab |
US11951207B2 (en) * | 2016-06-30 | 2024-04-09 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
FR3054444A1 (fr) * | 2016-07-29 | 2018-02-02 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Composition orale d'anticorps anti-tnf alpha |
WO2018039499A1 (fr) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Modification de protéines de cellules hôtes |
WO2018122053A1 (fr) * | 2016-12-29 | 2018-07-05 | F. Hoffmann-La Roche Ag | Formulation d'anticorps anti-angiopoïétine-2 |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EA201992630A1 (ru) | 2017-05-06 | 2020-04-29 | Ридженерон Фармасьютикалз, Инк. | Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf |
KR20210084695A (ko) | 2017-07-06 | 2021-07-07 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
CN111479618B (zh) | 2017-12-22 | 2022-08-02 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
US20190225689A1 (en) * | 2018-01-22 | 2019-07-25 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-pd-1 antibodies |
AU2019215363A1 (en) | 2018-01-31 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
MX2020008988A (es) | 2018-02-28 | 2020-09-28 | Regeneron Pharma | Sistemas y metodos para la identificacion de contaminantes virales. |
JP7315565B2 (ja) | 2018-03-19 | 2023-07-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | マイクロチップキャピラリー電気泳動アッセイおよび試薬 |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
CA3100035A1 (fr) | 2018-08-27 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Utilisation de spectroscopie raman dans une purification en aval |
CN112601963B (zh) | 2018-08-30 | 2024-05-24 | 瑞泽恩制药公司 | 用于表征蛋白质复合物的方法 |
EP3857237B1 (fr) | 2019-01-16 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Méthodes de caractérisation des liaisons disulfure |
MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
AU2020227580A1 (en) * | 2019-02-25 | 2021-09-30 | Pharmabcine Inc. | Anti-Ang2 antibody and use thereof |
US11730812B2 (en) * | 2019-03-08 | 2023-08-22 | Boehringer Ingelheim International Gmbh | Anti-IL-36R antibody formulations |
KR20220007586A (ko) | 2019-05-13 | 2022-01-18 | 리제너론 파마슈티칼스 인코포레이티드 | 개선된 경쟁적 리간드 결합 검정 |
CA3216345A1 (fr) | 2019-09-24 | 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Systemes et procedes d'utilisation et de regeneration de chromatographie |
EP4065086A1 (fr) | 2019-11-25 | 2022-10-05 | Regeneron Pharmaceuticals, Inc. | Formulations à libération prolongée utilisant des émulsions non aqueuses |
CA3165060C (fr) | 2020-01-21 | 2023-06-20 | Yiming Zhao | Procedes de deglycosylation pour l'electrophorese de proteines glycosylees |
US20220031843A1 (en) * | 2020-07-08 | 2022-02-03 | Regeneron Pharmaceuticals, Inc. | Stabilized Formulations Containing Anti-CTLA-4 Antibodies |
JP2023542820A (ja) | 2020-08-31 | 2023-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 細胞培養成績を改善し、アスパラギン配列バリアントを軽減するためのアスパラギン供給戦略 |
KR20230113280A (ko) | 2020-11-25 | 2023-07-28 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 멤브레인 유화법을 사용한 지속 방출 제형 |
MX2023007225A (es) | 2020-12-17 | 2023-06-27 | Regeneron Pharma | Fabricacion de microgeles encapsuladores de proteina. |
JP2024503408A (ja) | 2021-01-20 | 2024-01-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 細胞培養におけるタンパク質力価の改善方法 |
JP2024512299A (ja) | 2021-03-03 | 2024-03-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質の粘度を定量及び変更するためのシステム及び方法 |
BR112023018665A2 (pt) | 2021-03-26 | 2023-10-03 | Regeneron Pharma | Métodos e sistemas para desenvolvimento de protocolos de mistura |
BR112023024984A2 (pt) | 2021-06-01 | 2024-02-20 | Regeneron Pharma | Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit |
WO2023039457A1 (fr) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | Procédé à haut rendement et fondé sur la spectrométrie de masse pour quantifier des anticorps et d'autres protéines contenant fc |
AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
TW202323817A (zh) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Ph建模及控制之系統及方法 |
WO2023059803A1 (fr) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Étalonnage et correction de ph-mètre |
CN118176167A (zh) | 2021-10-26 | 2024-06-11 | 瑞泽恩制药公司 | 用于产生实验室用水和分配处于不同温度的实验室用水的系统和方法 |
TW202346856A (zh) | 2022-03-18 | 2023-12-01 | 美商里珍納龍藥品有限公司 | 分析多肽變體的方法及系統 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
WO1993000807A1 (fr) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Procede de stabilisation de biomateriaux |
JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
AU670793B2 (en) | 1992-04-30 | 1996-08-01 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor VIII complex |
US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
EP0852951A1 (fr) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux |
US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
JP3919235B2 (ja) | 1997-06-13 | 2007-05-23 | ジェネンテク,インコーポレイテッド | 抗体製剤 |
ES2299241T3 (es) | 1998-03-17 | 2008-05-16 | Chugai Seiyaku Kabushiki Kaisha | Preventivos o remedios para enfermedades intestinales inflamatorias que contienen anticuerpos antagonistas del receptor il-6. |
JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
WO2002013860A1 (fr) | 2000-08-11 | 2002-02-21 | Chugai Seiyaku Kabushiki Kaisha | Preparations stabilisees contenant un anticorps |
AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
DE60235013D1 (de) * | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
SI1478394T1 (sl) | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
MXPA05008409A (es) * | 2003-02-10 | 2005-10-05 | Elan Pharm Inc | Formulacion de inmunoglobulina y metodo para la preparacion de la misma. |
ZA200507757B (en) | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
WO2005072772A1 (fr) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Compositions pharmaceutiques |
MX2007004247A (es) * | 2004-10-19 | 2007-06-12 | Amgen Inc | Agentes de aglutinacion especifica a angiopoyetina-2. |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
PL1838733T3 (pl) * | 2004-12-21 | 2012-02-29 | Medimmune Ltd | Przeciwciała skierowane przeciwko angiopoetynie-2 i ich zastosowania |
CA2995971A1 (fr) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Formulations d'antagonistes du facteur vegf |
EA012801B1 (ru) | 2005-06-14 | 2009-12-30 | Эмджен Инк. | Самобуферирующиеся композиции белков |
JP5216002B2 (ja) | 2006-06-16 | 2013-06-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 硝子体内投与に適したvegfアンタゴニスト製剤 |
RU2509085C2 (ru) * | 2008-01-28 | 2014-03-10 | Медиммун Лимитед | Стабилизированные антитела против ангиопоэтина-2 и их применение |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
RU2011140498A (ru) | 2009-03-06 | 2013-04-20 | Дженентек, Инк. | Препарат антител |
JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
IT1396433B1 (it) * | 2009-11-16 | 2012-11-23 | Rolic Invest Sarl | Impianto eolico per la generazione di energia elettrica e metodo per realizzare un pilone del suddetto impianto eolico. |
AU2010320515B2 (en) | 2009-11-20 | 2013-05-02 | Biocon Limited | Formulations of antibody |
JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
US8945559B2 (en) | 2010-10-06 | 2015-02-03 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies |
CN104169299B (zh) | 2012-01-23 | 2018-06-05 | 瑞泽恩制药公司 | 含抗Ang-2 抗体的稳定化制剂 |
US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
-
2013
- 2013-01-22 CN CN201380006367.8A patent/CN104169299B/zh not_active Expired - Fee Related
- 2013-01-22 JO JOP/2013/0020A patent/JO3533B1/ar active
- 2013-01-22 MY MYPI2014001985A patent/MY164611A/en unknown
- 2013-01-22 BR BR112014017882A patent/BR112014017882A2/pt not_active Application Discontinuation
- 2013-01-22 NZ NZ627859A patent/NZ627859A/en not_active IP Right Cessation
- 2013-01-22 KR KR1020147023205A patent/KR102063028B1/ko active IP Right Grant
- 2013-01-22 US US13/746,669 patent/US9402898B2/en active Active
- 2013-01-22 EA EA201491414A patent/EA033387B1/ru unknown
- 2013-01-22 JP JP2014553508A patent/JP6113756B2/ja not_active Expired - Fee Related
- 2013-01-22 CA CA2861062A patent/CA2861062A1/fr not_active Abandoned
- 2013-01-22 MX MX2014008874A patent/MX357393B/es active IP Right Grant
- 2013-01-22 SG SG11201403792TA patent/SG11201403792TA/en unknown
- 2013-01-22 WO PCT/US2013/022473 patent/WO2013112438A1/fr active Application Filing
- 2013-01-22 AU AU2013212587A patent/AU2013212587B2/en not_active Ceased
- 2013-01-22 EP EP13702556.5A patent/EP2807190B1/fr active Active
- 2013-01-23 TW TW102102503A patent/TWI615149B/zh not_active IP Right Cessation
- 2013-01-23 AR ARP130100204A patent/AR089787A1/es not_active Application Discontinuation
- 2013-01-23 UY UY0001034587A patent/UY34587A/es not_active Application Discontinuation
-
2014
- 2014-07-02 IL IL233482A patent/IL233482B/en active IP Right Grant
- 2014-07-15 PH PH12014501628A patent/PH12014501628A1/en unknown
- 2014-07-22 CL CL2014001930A patent/CL2014001930A1/es unknown
- 2014-08-07 MA MA37279A patent/MA35904B1/fr unknown
-
2015
- 2015-06-01 HK HK15105209.9A patent/HK1204631A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
MX2014008874A (es) | 2014-09-01 |
CA2861062A1 (fr) | 2013-08-01 |
MY164611A (en) | 2018-01-30 |
NZ627859A (en) | 2015-09-25 |
JP2015505539A (ja) | 2015-02-23 |
WO2013112438A1 (fr) | 2013-08-01 |
EP2807190A1 (fr) | 2014-12-03 |
AU2013212587B2 (en) | 2017-07-20 |
HK1204631A1 (en) | 2015-11-27 |
US20130186797A1 (en) | 2013-07-25 |
AU2013212587A1 (en) | 2014-08-21 |
SG11201403792TA (en) | 2014-10-30 |
EA201491414A1 (ru) | 2014-12-30 |
EP2807190B1 (fr) | 2018-12-26 |
UY34587A (es) | 2013-07-31 |
CN104169299A (zh) | 2014-11-26 |
CN104169299B (zh) | 2018-06-05 |
PH12014501628B1 (en) | 2014-10-13 |
BR112014017882A2 (pt) | 2017-06-27 |
MX357393B (es) | 2018-07-06 |
JP6113756B2 (ja) | 2017-04-12 |
KR102063028B1 (ko) | 2020-01-07 |
KR20150000873A (ko) | 2015-01-05 |
EA033387B1 (ru) | 2019-10-31 |
JO3533B1 (ar) | 2020-07-05 |
US9402898B2 (en) | 2016-08-02 |
AR089787A1 (es) | 2014-09-17 |
TWI615149B (zh) | 2018-02-21 |
IL233482A0 (en) | 2014-08-31 |
IL233482B (en) | 2019-06-30 |
TW201343177A (zh) | 2013-11-01 |
CL2014001930A1 (es) | 2014-10-03 |
PH12014501628A1 (en) | 2014-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35904B1 (fr) | Formulations stabilisées contenant des anticorps anti-ang2 | |
MA33993B1 (fr) | Formulations stabilisées contenant des anticorps contre le récepteur de l'interleukine-6 (il-6r) | |
MA37645B1 (fr) | Formulations stabilisées contenant des anticorps anti-dll4 | |
EP4249512A3 (fr) | Formulation stable d'anticorps | |
WO2008008364A3 (fr) | Compositions liquides de phényléphrine à stabilité améliorée | |
MX366337B (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). | |
MA30470B1 (fr) | Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste. | |
MA33592B1 (fr) | Formulations pharmaceutiques hautement concentrées | |
WO2010100200A3 (fr) | Préparation d'anticorps lyophilisée | |
MA34286B1 (fr) | Compositions pharmaceutiques et procédés pour les fabriquer | |
WO2011163649A3 (fr) | Procédés et compositions pour la délivrance au snc d'iduronate-2-sulfatase | |
WO2006135480A3 (fr) | Formulations pharmaceutiques | |
FR2925333B1 (fr) | Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives | |
WO2008128775A3 (fr) | Composition pharmaceutique stabilisée contenant de la prégabaline | |
TW200640487A (en) | Combination of XOLAIR with immunosuppressive agent | |
ZA200509222B (en) | Stable, aqueous solution of human erythropoietin, not containing serum albumin | |
MX2021011137A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33. | |
MA31014B1 (fr) | Vaccin contre la leishmania canine. | |
PT1200088E (pt) | Composicao contendo paracetamol e drotaverina | |
WO2012156665A3 (fr) | Procédés et compositions liés à la sensibilité plaquettaire | |
GT200600073A (es) | Agentes farmaceuticos que contienen complejos metalicos con contenido de fluoroalquilo y epotilonas. | |
Kuipers et al. | Acrolein in Cigarette Smoke Extract Binds to Glutaredoxin 1. | |
TH108942A (th) | เกลือของตัวยับยั้งเอนไซม์ชนิดใหม่นอกจากนั้นที่เปลี่ยนแองจิโอเทนซินด้วยกรดตัวให้ no กระบวนการเตรียมเกลือชนิดเหล่านั้นและองค์ประกอบที่เป็นเภสัชภัณฑ์ที่มีเกลือชนิดเหล่านั้น | |
WO2005056581A3 (fr) | Peptide susceptible de se lier specifiquement a un recepteur de chimiokine et son utilisation | |
ITBO20060369A1 (it) | Fustellato per la fabbricazione di pacchetti rigidi con coperchio ribaltabile e con spigoli arrotondati o smussati, in particolare per sigarette, o simili e metodo di piegatura dello stesso per la realizzazione del pacchetto rigido. |